Protocol Ledger

NCT04693637 · Phase II/III · COMPLETED

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Interventional Phase II/III clinical trial protocol NCT04693637 sponsored by AlloVir in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-15 Enrollment: 26 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04693637
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)26 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04693637
Protocol FieldVerified Registry Value
NCT IdentifierNCT04693637
Consolidated Lead SponsorAlloVir
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment26 participants (ACTUAL)
Registered Start Date2021-01-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI